



# Ortho Regenerative Technologies Announces Voting Results of its Annual General and Special Meeting of Shareholders

MONTREAL, July 21, 2021 /CNW Telbec/ - [Ortho Regenerative Technologies Inc.](#) (CSE: ORTH) (OTCQB: ORTIF) ("**Ortho**" or the "**Company**"), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held via videoconference on July 21, 2021.

## **Election of Directors**

The following nine (9) nominees were elected as Directors of the Company to hold office until the next Annual Meeting of Shareholders or until their successors are elected or appointed:

Mr. Michael Atkin  
Mr. Pierre Laurin  
Mr. Claude LeDuc  
Dr. Brent Norton  
Mr. Patrick O'Donnell  
Mr. Steve Saviuk  
Mr. Tom E.S. Wright  
Mr. Howard P. Walthall  
Mr. Tim Cunningham

## **Appointment of Auditors**

Ernst & Young LLP was appointed as auditor of the Company to hold office until the next Annual Meeting of Shareholders, and the Board of Directors was authorized to fix the auditor's remuneration.

## **Equity Incentive Plan**

The Equity Incentive Plan, as more particularly described in the Circular, was approved by a resolution of Disinterested Shareholders. The purpose of this Plan is to allow for certain discretionary bonuses and similar awards as an incentive and reward for selected Eligible Participants related to the achievement of long-term financial and strategic objectives of the Corporation and the resulting increases in shareholder value. This Plan is intended to promote a greater alignment of interests between the shareholders of the Corporation and the selected Eligible Persons by providing an opportunity to acquire Shares as long-term investments and proprietary interests in the Corporation.

## **About Ortho Regenerative Technologies Inc.**

Ortho is a clinical stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries. Our proprietary RESTORE technology platform is a proprietary muco-adhesive Chitosan-based biopolymer matrix, specifically designed to deliver biologics such as Platelet-Rich Plasma (PRP) or Bone Marrow Aspirate Concentrate (BMAC), to augment and guide the regeneration of new tissue in various musculoskeletal conditions. ORTHO-R, our lead Chitosan-PRP

hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports-related injuries to tendons, meniscus and ligaments. Other formulations are being developed for cartilage repair, bone void filling and osteoarthritis treatment. The proprietary Chitosan-PRP combination ORTHO-R implant can be directly applied into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant potential of our technology platform, Ortho continues to assess new therapeutic target uses outside of the soft tissue repair field. Further information about Ortho is available on the Company's website at [www.orthorti.com](http://www.orthorti.com) and on SEDAR at [www.sedar.com](http://www.sedar.com). Also follow us on LinkedIn and Twitter.

## Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Company's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Ortho Regenerative Technologies Inc.

📄 View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/July2021/21/c5781.html>

%SEDAR: 00037950E

**For further information:** Claude LeDuc, President and Chief Executive Officer, (514) 693-8804, [leduc@orthorti.com](mailto:leduc@orthorti.com); Frederic Dumais, Director Communications and Investor Relations, (514) 782-8803, [dumais@orthorti.com](mailto:dumais@orthorti.com)

CO: Ortho Regenerative Technologies Inc.

CNW 12:57e 21-JUL-21